The mission of the Cancer Immunology Program is to generate new insights into the mechanisms that regulate the anti-tumor immune response and to translate this information into efficacious immunotherapies for cancer patients. The central hypothesis is that a deeper understanding ofthe requirements for effective innate and adaptive host responses will advance the development of treatment strategies that overcome tumor immune escape. The Program is led by G. Dranoff(DFCI) and K. Wucherpfennig (DCFI), and includes 86 faculty members representing all seven member institutions and 13 departments of HMS and HSPH. The Program has been NCI funded since the consortium received its first CCSG in 2000, and was rated outstanding at the last CCSG renewal in 2005. In the current budget year, Program members generated $37.5 million (total costs) in peer-reviewed grant support, with $8.4 million in funding from the NCI. The total number of publications from members of the Program over the project period was 1,508 (2006 to 2010);14% were intra-programmatic, 24% were inter-programmatic and 18% were inter-institutional. Thematically. the Program is broadly divided into investigative efforts in bone marrow transplantation, adoptive cellular therapies and cancer vaccines. Regular workshops serve to disseminate ongoing research findings, increase knowledge of cancer immunology within the Harvard Immunology community and stimulate collaborations among basic and clinical scientists. An active clinical immunotherapy program across the Dana-Farber/Harvard Cancer Center institutions provides interactions and collaborations between the Program and numerous disease-focused Programs. Multiple DF/HCC Shared Resources advance the Program's research and clinical activities. During the current project period, the Program has had three specific aims. These are: 1. To increase our understanding of the immune mechanisms that contribute to tumor development. 2. To improve the therapeutic activity and minimize the toxicities of bone marrow transplantation and adoptive cellular therapies. 3. To improve the therapeutic activity and minimize the toxicities of cancer vaccines.

Public Health Relevance

The Cancer Immunology Program of DF/HCC aims to generate new information about the immune response to cancer and then to apply this knowledge to advance the development of efficacious and safe immunotherapies. The Program brings together laboratory and clinical scientists to accelerate the translation of basic discoveries in immunology to the improvement of patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006516-47
Application #
8227656
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$93,207
Indirect Cost
$69,350
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33
Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:
Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192
Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95
Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9
Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57
Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90
Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80
Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608

Showing the most recent 10 out of 177 publications